Develops programmable oligonucleotide therapeutics that autonomously silence disease-causing RNAs in human and pathogen cells. This platform targets genetically driven diseases, chronic conditions, and multidrug-resistant infections, offering safer and more precise treatments for conditions like cancer, ALS, and MRSA.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are driven by the expression of specific RNAs within human and pathogen cells. Current treatment options for these diseases may lack the precision to target the underlying genetic causes or may have significant side effects.
Solution
1E Therapeutics is developing a new class of programmable oligonucleotide therapeutics designed to autonomously silence disease-causing RNAs in human and pathogen cells. Their patented platform creates targeted therapies that address chronic and life-threatening indications, as well as emerging and evolving pathogens. This approach offers the potential for safer and more precise treatments for a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions. By directly silencing the RNAs responsible for disease, 1E Therapeutics aims to provide more effective and targeted therapeutic interventions.
Target Audience
The primary target audience includes patients suffering from genetically driven diseases, chronic conditions, and multidrug-resistant infections, as well as healthcare providers seeking more precise and effective treatment options.
Features
- Programmable oligonucleotide therapeutics for targeted RNA silencing
- Patented platform for creating safer and more targeted therapies
- Ability to address a wide array of indications, including genetically driven diseases, infectious diseases, and chronic conditions
- Designed to autonomously and precisely silence disease-causing RNAs in human or pathogen cells